Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Transcranial magnetic stimulation is being tested in multiple clinical trials as a potential treatment for early-stage dementia, and preliminary results are genuinely encouraging. Unlike medications that work systemically throughout the brain, TMS uses targeted magnetic pulses to stimulate specific neural networks involved in memory and cognition—potentially slowing cognitive decline in patients with mild-to-moderate Alzheimer’s disease and mild cognitive impairment. A landmark 2025 study published in Oxford Academic found that when researchers used rTMS to target the precuneus region of the brain, they observed measurable improvements in cognitive function over a 52-week period, with gains showing up on standardized tests like the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and the Mini-Mental State Examination (MMSE).
What makes these findings noteworthy is that TMS is completely non-invasive—there’s no surgery, no implants, and no systemic medications to manage side effects. Instead, magnetic coils placed against the scalp deliver precisely timed pulses that stimulate brain activity. This article explores what researchers have learned so far, which patients might benefit most, what the actual treatment looks like, and why the scientific community is cautiously optimistic about TMS despite the research still being in relatively early stages. We’ll also discuss the significant limitations that remain before TMS becomes a standard treatment option rather than an experimental one.
Table of Contents
- How Targeted Brain Stimulation Addresses Early-Stage Dementia
- Clinical Evidence From Recent Trials and Studies
- What the Treatment Protocol Looks Like in Practice
- Which Patients Show the Greatest Promise With TMS
- Key Research Limitations and What They Mean
- Network-Targeted and Personalized Approaches Show Greater Promise
- The Research Road Ahead and Future Clinical Availability
- Conclusion
How Targeted Brain Stimulation Addresses Early-Stage Dementia
The mechanism behind TMS for dementia centers on its ability to strengthen neural connections and promote neuroplasticity—essentially helping the brain rewire itself around areas affected by neurodegeneration. In early-stage Alzheimer’s disease and mild cognitive impairment, the brain hasn’t yet undergone the severe structural changes that characterize advanced dementia, which means there’s still a therapeutic window where targeted stimulation can potentially slow the progression of decline. When magnetic pulses are applied to regions involved in memory storage and retrieval, they can trigger the brain to increase activity and strengthen the neural networks supporting cognition. The UCLA Health research team recently completed a phase 2 clinical trial that demonstrated this principle in action. In their 52-week study of 32 volunteers aged 56 to 88, researchers used TMS to target the brain’s memory storage network directly, comparing the results to an inactive placebo treatment.
Participants who received the active stimulation showed slower symptom development, including less rapid memory loss, compared to the control group. This direct comparison is crucial because it shows that TMS isn’t just producing general brain stimulation benefits—it’s actually impacting the specific cognitive domains most affected by dementia. However, it’s important to recognize that stimulating the brain isn’t a one-size-fits-all proposition. TMS appears to work best when the target location is carefully chosen based on an individual’s brain connectivity patterns and the specific cognitive domains they’re struggling with. Some people’s brains may respond better to stimulation of the precuneus (involved in self-referential thought and memory), while others might benefit more from targeting the prefrontal cortex (involved in executive function) or memory-specific networks. This emerging understanding is why researchers are moving away from standardized protocols toward personalized, network-targeted approaches.
Clinical Evidence From Recent Trials and Studies
The most recent and rigorous evidence comes from the 2025 precuneus rTMS study, which stands out for its length and methodological rigor. Over 52 weeks, researchers randomly assigned patients with mild-to-moderate Alzheimer’s disease to either receive TMS targeting the precuneus or a control treatment. Outcomes were measured using multiple validated cognitive scales, and researchers also tracked functional improvements—whether patients could perform daily activities more effectively. The results showed that rTMS significantly slowed cognitive decline compared to control, with measurable benefits showing up in both cognitive test scores and real-world functioning. Beyond this landmark study, researchers are moving into more sophisticated treatment approaches. In February 2025, Sinaptica partnered with device manufacturer Nexstim to launch a Phase 2 clinical trial testing a second-generation system that combines TMS with transcranial electrical stimulation—essentially using two types of electrical brain stimulation in tandem.
This trial is enrolling up to 60 patients with early-stage Alzheimer’s disease across multiple centers in Italy. The rationale is that combining two complementary stimulation techniques might produce stronger or more durable effects than either approach alone. The fact that researchers are moving this quickly into phase 2 trials signals confidence in the underlying science. A broader meta-analysis examining all available studies of rTMS in Alzheimer’s disease found that the treatment significantly improved global cognitive function and activities of daily living overall, but the picture is more nuanced when you look at specific cognitive domains. Memory, language, executive function, and motor skills showed variable responses across different studies—some patients showed meaningful improvement while others did not. This variability is why personalized, network-targeted protocols are increasingly becoming the focus. Rather than giving everyone the same treatment protocol, researchers are learning to customize the stimulation targets based on which brain networks are most affected in that individual patient.
What the Treatment Protocol Looks Like in Practice
If you or a family member are considering TMS for early-stage dementia, it’s helpful to understand what the treatment schedule typically involves. The standard protocol consists of two phases: an intensive initial phase and a longer maintenance phase. During the first two weeks, patients receive TMS five days per week—this concentrated treatment is designed to establish stronger changes in brain connectivity and neural activity. After those initial two weeks, the frequency drops significantly to maintenance treatment of one to two sessions per week, which continues for up to six months. The goal of the maintenance phase is to sustain and reinforce the neural changes initiated during the intensive period. A typical TMS session lasts around 30 to 45 minutes. The patient sits in a comfortable chair, and a trained technician places magnetic coils against the scalp, typically secured with a positioning system so the stimulation is directed precisely to the intended brain region.
The person remains awake and alert throughout—there’s no sedation or anesthesia—and can usually drive themselves home afterward. Some patients report a mild tapping sensation on the scalp during stimulation, and a few experience mild headaches afterward, but serious side effects are rare. The key practical consideration is consistency: the treatments work best when patients complete the full course and stick to the schedule. One important limitation to mention is that the two-phase protocol described above is based on the research protocols used in clinical trials, not yet on widespread clinical practice. Because TMS for dementia is still experimental, treatment schedules may vary between research centers, and there’s still debate about optimal frequency and duration. Additionally, patients with certain types of implanted medical devices (like pacemakers or cochlear implants) may not be candidates for TMS, which reduces the potential treatment population. This is one of several reasons why TMS will likely remain a specialized treatment at research centers or highly equipped clinics rather than becoming available everywhere.
Which Patients Show the Greatest Promise With TMS
The strongest evidence for TMS benefit exists in patients with early-stage dementia—specifically those with mild cognitive impairment or mild-to-moderate Alzheimer’s disease. The research suggests this is because early-stage disease still allows for meaningful neuroplasticity and functional recovery, whereas advanced dementia with severe structural brain changes may have already crossed a point where targeted stimulation cannot reverse the damage. All of the recent clinical trials focus on this early-to-moderate window because that’s where the treatment appears most likely to be effective. Age appears to be less of a limiting factor than disease stage. The UCLA trial included participants ranging from 56 to 88 years old, with meaningful benefits observed across this wide age range. What matters more is cognitive reserve—roughly speaking, how much cognitive capacity the person has left to work with—rather than chronological age.
A cognitively active 80-year-old might benefit more than a less cognitively engaged 65-year-old. Additionally, the UCLA team found that properly targeted stimulation works best when directed at the neural networks most affected by that individual’s disease pattern. This is why emerging protocols emphasize personalized network mapping to identify which brain regions to target in each patient. There’s a trade-off to consider: earlier intervention might produce better outcomes, but early-stage dementia can be harder to diagnose with certainty. A diagnosis of mild cognitive impairment or early Alzheimer’s requires thorough neuropsychological testing and imaging, and the earlier in the process you are, the less obvious the changes. This means that if TMS becomes a standard treatment, healthcare systems will need to invest in better early detection methods to identify patients who could benefit most. For now, anyone considering TMS for dementia should expect it to be part of a comprehensive evaluation that includes cognitive testing, brain imaging, and careful diagnostic confirmation rather than a first-line treatment.
Key Research Limitations and What They Mean
While the recent results are encouraging, it’s essential to understand the substantial limitations in the current evidence base. The most important limitation is sample size—most studies, including even the recent 2025 precuneus trial, involve fewer than 60 participants. By contrast, when FDA evaluates new medications for dementia, it typically reviews data from hundreds or thousands of patients across multiple trials. With TMS, we currently have a handful of smaller, mostly single-center studies. This means that while the trends are positive, there’s not yet enough data to confidently predict how broadly effective TMS would be if deployed across many different patient populations and treatment centers. Another critical gap is protocol inconsistency. Different research teams have used different stimulation parameters—different frequencies, different intensities, different total number of pulses, and different target locations.
While this is typical in early-stage research, it makes it harder to compare results across studies and to determine what the optimal protocol actually is. One center might find strong benefits using one TMS protocol while another center using a slightly different approach might see minimal effects. This inconsistency is probably why the meta-analysis found variable effects across cognitive domains and different studies—we’re essentially looking at multiple different treatments, not one unified approach. A final limitation that must be mentioned: the lack of long-term follow-up data. Most TMS trials follow patients for weeks to months, but we don’t yet know what happens one, two, or five years after treatment ends. Does the benefit persist? Does the brain eventually return to its baseline decline trajectory? Would patients need periodic TMS “booster” sessions indefinitely? These are critical questions for any potential disease-modifying treatment, and we simply don’t have the answers yet. This is why TMS remains classified as research-stage rather than an established clinical treatment.
Network-Targeted and Personalized Approaches Show Greater Promise
As the field has evolved, researchers have moved away from the idea that everyone with early dementia should receive identical TMS to the same brain location. Instead, emerging evidence strongly supports network-targeted and personalized TMS protocols. The concept is based on understanding that dementia affects different people’s brains differently—some people might have greater dysfunction in memory networks, while others have more prominent frontal lobe or temporal lobe involvement. By using functional brain imaging to map each individual’s specific network dysfunction and then targeting stimulation to the most affected networks, researchers are getting better results than earlier one-size-fits-all approaches. An example of this personalization in action comes from the 2025 precuneus study. The researchers didn’t simply put the TMS coil in the same place for every patient.
Instead, they carefully selected the precuneus as the target specifically because functional imaging showed that this region had reduced connectivity in their patient population with mild-to-moderate Alzheimer’s. They were essentially asking: “Where is the network dysfunction most pronounced in these patients, and where is stimulation most likely to help?” This targeted approach yielded measurable benefits in both cognitive and functional outcomes. Looking forward, the next generation of TMS for dementia will likely involve even more sophisticated personalization. Researchers may use advanced neuroimaging to create individual brain maps, genetic or biomarker testing to identify which pathways are most disrupted in a specific patient, and computational modeling to predict which stimulation protocol would work best for that person. This represents a shift from “disease-based” treatment (treating all Alzheimer’s the same way) to “network-based” or “patient-specific” treatment. While this is a positive development scientifically, it also means that TMS for dementia, if it becomes a clinical treatment, will likely be more complex and require more sophisticated infrastructure than current options.
The Research Road Ahead and Future Clinical Availability
As of April 2026, TMS remains a research-stage treatment for dementia and is not yet FDA-approved as a standard therapeutic option. The pathway forward likely involves several more years of clinical trials. The February 2025 Phase 2 trial with Sinaptica and Nexstim testing dual stimulation should provide crucial data about whether combining TMS with transcranial electrical stimulation produces superior outcomes. If that trial is successful, it would eventually move toward Phase 3 trials—larger, multi-center studies that would generate the evidence base needed for FDA consideration.
The broader research agenda also includes clarifying which patients benefit most, determining optimal treatment protocols, understanding whether benefits persist long-term, and investigating whether periodic maintenance treatments might be necessary. Simultaneously, researchers are exploring whether TMS might work better in combination with existing dementia medications like aducanumab or lecanemab, or with other interventions like cognitive training or lifestyle modification. None of these questions have definitive answers yet, which is why every current TMS study for dementia carries an explicit “research” designation and why informed consent emphasizes that this is not yet proven treatment. For anyone interested in TMS for dementia currently, clinical trial participation through major academic medical centers is the primary avenue for access.
Conclusion
Transcranial magnetic stimulation represents a genuinely novel approach to early-stage dementia—a non-invasive, network-targeted intervention that stimulates the brain to strengthen cognitive networks undermined by neurodegeneration. Recent clinical trials, particularly the 2025 precuneus study and the UCLA phase 2 trial, have demonstrated that properly targeted TMS can slow cognitive decline and preserve functional ability in patients with mild-to-moderate Alzheimer’s disease. The safety profile is favorable, the mechanism is scientifically rational, and the preliminary results are encouraging.
This is legitimately promising research that has moved beyond theoretical possibility into demonstrated clinical signal. However, the treatment remains in research stages because the current evidence base, while positive, is limited by small sample sizes, inconsistent treatment protocols across studies, lack of long-term follow-up data, and insufficient evidence to predict how broadly effective TMS would be across diverse patient populations. Before TMS becomes a standard clinical option rather than a research experiment, several more years of rigorous testing will likely be necessary. If you or a family member have early-stage dementia and are interested in TMS, the appropriate next step is to consult with a neurologist or memory care specialist at an academic medical center to ask whether clinical trial participation might be an option and what other evidence-based approaches are available for early intervention and cognitive support.
You Might Also Like
- How Focused Ultrasound Therapy Is Being Tested to Open the Blood Brain Barrier for Dementia Drugs
- Why Learning to Cook a New Recipe Each Week Combines Multiple Dementia Prevention Activities
- Why Walking With a Friend Provides More Brain Benefits Than Walking Alone for Dementia Prevention
For more, see Alzheimer’s Association — clinical trials.
